Dr. Konduri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3410 Worth St
Dallas, TX 75246Phone+1 214-370-1000Fax+1 214-370-1202
Education & Training
Baylor University Medical CenterFellowship, Hematology and Medical Oncology, 2001 - 2003
Rush University Medical CenterResidency, Internal Medicine, 1995 - 1998
Delhi University College of Medical SciencesClass of 1994
Certifications & Licensure
TX State Medical License 2002 - 2025
IL State Medical License 1995 - 2008
OK State Medical License 1998 - 2002- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC Start of enrollment: 2008 Jan 08
- Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
- A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Publications & Presentations
PubMed
- Biomarker Testing for Actionable Alterations in NSCLC-Perspectives from US-Based Academic and Community Oncologists: A Podcast.Wade T Iams, Kartik Konduri
Advances in Therapy. 2023-12-01 - 3 citationsLocally Advanced Inflammatory Myofibroblastic Tumor Treated With Targeted Therapy: A Case Report and Literature Review.Charis Durham, Matthew Clemons, Alwin Alias, Kartik Konduri
Cureus. 2022-07-01 - 30 citationsRandomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)David R. Spigel, Robert M. Jotte, John Nemunaitis, Merrill Kingman Shum, Jeffrey A. Schneider
Journal of Thoracic Oncology. 2021-02-01
Press Mentions
OncLive® Presents State of the Science Summit™ on Non-Small Cell Lung CancerApril 16th, 2019
Low Dose CT Scan May Save LivesNovember 20th, 2018
Clinical Trials Highlight Biomarker Progress in Lung CancerFebruary 21st, 2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
